Leland Chung

Title: Innovations by Leland Chung in Cancer Treatment

Introduction

Leland Chung, based in Los Angeles, California, is an innovative inventor focused on advancing medical research and treatment methods, specifically in the field of cancer. His work in the development of monoamine oxidase inhibitors (MAOIs) has the potential to revolutionize the treatment and diagnosis of prostate cancer.

Latest Patents

Chung holds a patent for "Monoamine oxidase inhibitors and methods for treatment and diagnosis of prostate cancer." This patent discloses a mechanism of monoamine oxidases (MAOs) driven epithelium-to-mesenchymal transition (EMT) and outlines methods for treating cancer by inhibiting or suppressing MAOs in cancer cells. The invention presents novel MAO inhibitors, including small molecules, siRNA, shRNA, antisense oligonucleotides, aptamers, decoys, and pharmaceutical compositions that are useful for disrupting the workings of MAOs in cancer treatment. Moreover, the patent includes a class of conjugates formed by covalently linking near infrared dye 783, IR-780, and MHI-148 to a MAO inhibitor, such as clorgyline, with and without nanoparticle encapsulation. Additional aspects of the invention comprise methods for creating the nano-conjugates, monitoring treatment progress in cancer patients by observing changes in MAO activity, and screening methods to identify patients at risk of cancer or to differentiate between various forms of cancer based on MAO activity levels and location.

Career Highlights

Leland Chung is affiliated with the University of Southern California, where he continues to contribute to medical science through his research and innovation. His patent is a testament to his dedication and expertise in the field of cancer research, especially concerning the roles of MAOs in cancer progression and treatment.

Collaborations

Chung has collaborated with esteemed colleagues such as Jean C. Shih and Haiyen E. Zhau. Their collective efforts enhance the research and practical applications of MAO inhibitors in medical treatments, emphasizing the importance of collaborative innovation in the scientific community.

Conclusion

Leland Chung’s contributions to cancer research, particularly through his patent on monoamine oxidase inhibitors, signify a meaningful advance in the medical field. By focusing on innovative pathways for treatment and diagnosis, Chung’s work represents the potential for better outcomes in prostate cancer management, reinforcing the significance of innovation in healthcare.